We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Committee Recommends Praluent for High Cholesterol Patients
Committee Recommends Praluent for High Cholesterol Patients
The Endocrinologic and Metabolic Drugs Advisory Committee voted 13 to 3 Tuesday to recommend approval of Sanofi and Regeneron’s cholesterol-lowering drug Praluent, but said more data is needed to support the drug’s effect on cardiovascular outcomes.